These include injection site pain, headache, dizziness, and rarely, hypersensitivity reactions
In medial collateral ligament (MCL) injury models, BPC-157 administered intraperitoneally (10 g or 10 ng/kg once daily), topically as a cream layer, or orally in drinking water consistently produced functional, biomechanical, macroscopic, and histological healing improvements throughout the 90-day study period
BPC-157, a 15-amino acid peptide derived from a protein in human gastric juice, exploded in popularity for its reported ability to accelerate tissue repair, reduce inflammation, and support gut healing
Side effect comparison: Nausea: Tirzepatide rates range from 12% to 33% depending on dose, comparable to cagrilintide Vomiting: Tirzepatide higher than cagrilintide Diarrhea: Similar rates Injection site reactions: Cagrilintide significantly higher than tirzepatide Fatigue: Tirzepatide fatigue is commonly reported, comparable to cagrilintide Some researchers are exploring cagrilintide combined with tirzepatide for potentially enhanced effects
Jani M, Barton A, Ho P
